Wire · opportunities
Roche's IgAN hopeful sefaxersen passes phase 3 test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 September 2026 · Fusion42 review
Roche's antisense drug sefaxersen has met primary endpoints in a phase 3 trial for IgA nephropathy, showing significant reduction in kidney damage markers and potential for at-home monthly injections, with ongoing studies to assess long-term kidney function.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 23 Sep 2026 and 25 Sep 2026.
◆ ◆ The Wire takeaway
You need to factor in the rising competition in IgA nephropathy treatments as Roche's monthly injectable drug could reshape patient convenience and market share. Prepare to explore partnerships or innovation around patient-friendly delivery methods now.
◆ Coverage
3 sources · first reported 23 Sep 2026 · latest 25 Sep 2026
◆ Related on Wire
◆ Topics